Science & evidence

Evidence should be visible, not implied.

MMS is designed to distinguish established care from emerging science, use recognised guidance where relevant and keep personal medical decisions under professional review.

Explore screening Ask Ling

Your MMS guide

Ling

I can help explain what the evidence says, what remains uncertain and which questions belong with your doctor.

Your MMS guide

Ling

I can help explain what the evidence says, what remains uncertain and which questions belong with your doctor.

Virtual health spokesperson

Physician-led care

Professional review before recommendations.

Personalised to you

No one-size-fits-all health pathway.

Trusted & private

Discretion, clarity and continuity.

Science + humanity

Evidence-aware, compassion-led.

The MMS evidence standard

Science before spectacle.

Know what is established. Know what is uncertain. Know when a doctor needs to decide.

Guideline-led

Screening and prevention should begin with recognised clinical guidance, then be adapted to the individual.

Context before conclusion

A laboratory value, image or wearable signal becomes meaningful only when interpreted with history, symptoms and risk.

Evidence has levels

Established care, promising evidence and emerging science should never be presented as if they carry the same certainty.

Trends matter

Repeated measurements can add context that a single snapshot cannot, especially when interpreted by a clinician.

Evidence changes. Personal decisions still require context and professional judgement.

Explore Science & Evidence

How MMS should use evidence

Scientific credibility comes from method, not decoration.

Use the strongest relevant evidence

Clinical guidelines, high-quality reviews and established professional standards should take priority over novelty or marketing appeal.

Prefer local relevance

Malaysian clinical guidance and regulation matter. International guidance can add context, but should not silently replace local standards.

Show uncertainty

Where evidence is incomplete, evolving or highly individual, MMS should say so visibly rather than implying certainty.

Separate education from medical decisions

Ling can explain concepts and evidence levels. Personal interpretation, diagnosis, prescribing and suitability decisions stay with qualified professionals.

Evidence in practice

Screening should answer a clinical question.

The point is not to order the largest panel. It is to use appropriate measurements to clarify risk, then interpret them in context.

Malaysia MOH clinical guidelines ↗

Established screening

USPSTF Grade A

Blood pressure

Recognised preventive guidance supports screening adults for hypertension, with confirmation outside the clinic before treatment when appropriate.

USPSTF ↗

Risk-led screening

USPSTF Grade B

Glucose risk

Screening for prediabetes and type 2 diabetes is recommended for selected asymptomatic adults based on age and weight-related risk.

USPSTF ↗

Age + risk context

USPSTF A / B

Colorectal cancer

Average-risk colorectal cancer screening is recommended from age 45 through 75 in current USPSTF guidance, with later decisions individualised.

USPSTF ↗

These examples illustrate U.S. preventive guidance and its evidence grading, not a universal MMS screening schedule. Malaysian guidance, personal and family history, symptoms, sex, age, prior results and physician judgement may change what is appropriate.

Clinical governance

Intelligence is useful only when responsibility is clear.

MMS should make the handoff between technology and medicine visible. Data can be organised digitally; interpretation and clinical decisions remain accountable to qualified professionals.

Data quality

Use validated measurements where possible, record context and avoid treating one isolated number as a conclusion.

Ling organises

Ling can explain terminology, show trends and prepare questions without making a diagnosis.

Doctor interprets

Clinical significance depends on history, symptoms, examination, prior results, medications and professional judgement.

Plan is documented

Next steps should be explicit: what to do, what to watch, what to repeat and what does not need action yet.

Transparent uncertainty

Not every result needs action and not every emerging idea deserves recommendation.

Professional accountability

Diagnosis, prescribing and treatment suitability stay under qualified clinical review.

Continuity

What changes over time matters more when prior context remains visible and comparable.

Source hierarchy

Not all evidence deserves equal weight.

MMS should make the quality of the source visible. A new idea can be interesting without being clinically established, and a compelling story is not the same thing as proof.

Clinical guidelines & consensus standards

Recognised local and international guidance provides the strongest starting framework for routine preventive decisions.

Systematic reviews & high-quality trials

Useful for understanding treatment effects, limitations and where evidence is consistent or mixed.

Well-designed observational evidence

Can reveal associations and long-term patterns, but usually carries more uncertainty about cause and effect.

Early clinical & mechanistic evidence

Helpful for generating hypotheses and understanding plausibility, but not enough on its own to promise outcomes.

Testimonials, influencer claims & vendor marketing

May be useful for understanding interest or experience, but should not be treated as clinical proof.

Ask

What kind of evidence is this?

Check

Does it apply to this person and this indication?

Decide

What level of certainty is reasonable?

Evidence hierarchy

Not every health innovation deserves the same confidence.

MMS should make the level of certainty visible before discussing suitability. That protects trust and makes advanced care easier to understand.

Established

Standard preventive and clinical care

Approaches supported by mature guidelines, routine clinical use and clearer benefit–risk expectations.

Evidence-supported

Useful for selected people

Approaches with meaningful evidence that still depend strongly on indication, patient selection, clinician judgement and context.

Emerging

Promising, but not settled

Newer diagnostics or interventions where evidence, long-term outcomes, regulation or appropriate use may still be evolving.

Investigational

Research, not routine care

Interventions that should be discussed with explicit uncertainty, regulatory awareness and no implied outcome promise.

This is an MMS communication framework, not a substitute for treatment-specific evidence review. The classification of any individual test or intervention should be based on current evidence, regulation and professional assessment.

Reference organisations

Framework reviewed Sep 2026

Sources patients can inspect for themselves.

References are not endorsements of MMS or of every MMS service. They show the type of recognised guidance and evidence framework MMS should use when communicating preventive health.

Recognised guidance

Evidence framework

↗

Malaysia

Ministry of Health Malaysia

Clinical Practice Guidelines across cardiovascular, endocrine, cancer and other areas provide the local reference layer.

Inspect source

↗

Global

World Health Organization

WHO guidance provides a global prevention and noncommunicable-disease framework, including recognised behavioural and metabolic risk factors.

Inspect source

↗

Prevention

U.S. Preventive Services Task Force

USPSTF recommendations provide transparent grading and evidence review for many preventive screening decisions.

Inspect source

↗

Cardiovascular

American Heart Association

AHA frameworks such as Life's Essential 8 provide a recognised model for cardiovascular health behaviours and factors.

Inspect source

Begin

Understand the evidence before deciding what is right for you.

Ling can explain the framework. Your doctor decides what applies to your health.

Start Health Discovery Ask Ling